IS Pharma (LON:ISPH) snaps up the rights to Episil
The international speciality pharmaceutical company is on the acquisition trail again!
The Group has announced the acquisition for €1.75 million and royalties of the exclusive rights for Episil, an oncology supportive care product developed by Camurus AB (‘Camurus’), a privately owned Swedish life science company. Episil is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment. Episil creates a strongly bioadhesive FluidCrystal® film that protects sensitive and sore areas of the mouth providing prolonged pain reduction for at least eight hours. ISPH plans to launch Episil across Europe (excluding the Nordic countries) through 2010 and…